This Is What Whales Are Betting On Cytokinetics

Enormous financial players have taken a negative position on Cytokinetics (CYTK).

And individual investors should take note.

This came to our attention today when massive trades surfaced in the publicly available options data we monitor here at Benzinga.

It is unclear whether these are institutions or affluent individuals, but when such significant activity occurs with CYTK, it often indicates that someone is privy to nonpublic information.

So how do we discern the motives behind these investors’ actions?

Today, Benzinga’s options scanner identified 85 unusual options trades for Cytokinetics.

This is highly irregular.

The prevailing sentiment among these high-stakes traders tilts towards 62% bearish and 37% bullish.

Of all the exceptional options we unearthed, 9 are puts, amounting to $740,860, and 76 are calls, totaling $7,522,268.

Projected Price Targets

Assessing the volume and open interest in these contracts suggests that prominent players have been eyeing a price range between $36.0 and $125.0 for Cytokinetics in the past quarter.

Analyzing Volume & Open Interest

Scrutinizing the volume and open interest yields crucial insights into stock research. This data is essential for gauging liquidity and interest levels in Cytokinetics’s options at specific strike prices, within a range of $36.0 to $125.0, over the last month.

Cytokinetics Option Volume And Open Interest Over Last 30 Days

Significant Options Trades Detected:

Symbol	PUT/CALL	Trade Type	Sentiment	Exp. Date	Strike Price	Total Trade Price	Open Interest	Volume
CYTK	CALL	TRADE	BEARISH	01/19/24	$45.00	$1.1M	14.0K	252
CYTK	CALL	SWEEP	BEARISH	01/19/24	$45.00	$1.0M	14.0K	502
CYTK	PUT	TRADE	BEARISH	01/19/24	$80.00	$271.0K	725	1.0K
CYTK	CALL	TRADE	BEARISH	01/19/24	$60.00	$157.7K	18.4K	130
CYTK	CALL	TRADE	BEARISH	06/21/24	$40.00	$134.7K	551	475

About Cytokinetics

Cytokinetics Inc is a biotech company focused on developing treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company is working on treatments for conditions such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. These treatments are based on small molecules designed specifically to enhance muscle function and contractility. The company is developing muscle-directed investigational medicines with the potential to improve the health span of individuals enduring severe cardiovascular and neuromuscular diseases with impaired muscle function.

See also <!DOCTYPE html><html lang="en"><head> <meta charset="UTF-8"> <meta http-equiv="X-UA-Compatible" content="IE=edge"> <meta name="viewport" content="width=device-width, initial-scale=1.0"> <title>3 Stock Spinoffs Poised for Market Domination</title></head><body> <div> <h2>The Forgotten Gold Mine: Hidden Value in Spinoff Stocks</h2> <p>Spinoff stocks have long been cast aside by investors, deemed as unwanted remnants of bigger entities. However, diving deep into the world of spinoffs reveals a treasure trove waiting to be discovered. As investing guru Joel Greenblatt highlights in his timeless masterpiece "You Can Be a Stock Market Genius," these castaways often harbor unrealized potential when set free.</p> <h2>Solventum (SOLV): A Diamond in the Rough</h2> <p><strong>Solventum</strong> (NYSE:<span class="stock-ticker"><strong><u>SOLV</u></strong></span>) emerges as a promising player in the healthcare landscape after being spun off from industrial giant <strong>3M</strong> (NYSE:<span class="stock-ticker"><strong><u>MMM</u></strong></span>). With a stronghold in sterilization devices, dressings, tapes, this $8.2 billion revenue giant is ready to conquer. Despite a sluggish start post-separation, boasting revenues of $2 billion and $2.08 per share earnings, the stock remains undervalued. Priced at a discount due to an $8.3 billion debt burden from its previous parent, Solventum is on the path to redemption, making it a beacon in the sea of mediocrity.</p> <h2>Kenvue (KVUE): Unleashing Consumer Power</h2> <p><strong>Kenvue</strong> (NYSE:<span class="stock-ticker"><strong><u>KVUE</u></strong></span>) struts into the consumer health sector post its emancipation from <strong>Johnson & Johnson</strong> (NYSE:<span class="stock-ticker"><strong><u>JNJ</u></strong></span>). The custodian of iconic brands like Tylenol, Listerine, or Band-Aid, this $15 billion powerhouse flexes its muscles. With a formidable dividend legacy inherited from its erstwhile parent, Kenvue stands tall despite a 24% drop since its inception. Like a phoenix rising from the ashes, Kenvue is poised to soar high on the wings of trust and quality.</p> <h2>W.K. Kellogg (KLG): A Breakfast of Champions</h2> <p>If you had cereal for breakfast, chances are it bore the imprint of <strong>W.K. Kellogg</strong> (KLG). Stepping out of the shadows of its parent, this stalwart in the breakfast food industry is no stranger to your morning routine. With a legacy as rich as your favorite cornflakes, W.K. Kellogg is a stock to watch, destined to nurture portfolios much like it nurtures bodies.</p> </div></body></html><!DOCTYPE html><html><head> <title>The Rise of W.K. Kellogg in a Shrinking Cereal Market</title></head><body> The Rise of W.K. Kellogg in a Shrinking Cereal Market

Present Market Standing of Cytokinetics

With a trading volume of 4,158,467, CYTK’s price has dropped by -0.14% to $88.12.
Current RSI values suggest that the stock may be overbought.
The next earnings report is scheduled in 54 days.

Expert Opinions on Cytokinetics

In the past month, 5 industry analysts have shared their insights on this stock, presenting an average target price of $94.0.

An analyst from Morgan Stanley has downgraded its rating to Equal-Weight, adjusting the price target to $90.
An analyst from HC Wainwright & Co. maintains a Buy rating on Cytokinetics, with a target price of $94.
An analyst from Needham continues to support a Buy rating on Cytokinetics with a target price of $108.
An analyst from Truist Securities maintains a Buy rating for Cytokinetics, targeting a price of $86.
An analyst from Raymond James continues to advocate an Outperform rating for Cytokinetics, with a price target of $92.

Options are a riskier asset compared to simply trading the stock, but they offer higher profit potential. Serious options traders mitigate this risk by staying informed daily, gradually entering and exiting trades, considering multiple indicators, and closely following the markets.

For the latest options trade updates on Cytokinetics, Benzinga Pro provides real-time alerts.

5 Stocks Our Experts Predict Could Double In the Next Year

By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.